Comparison of Tissue-Engineered Dermis with Micronized Adipose Tissue and Artificial Dermis for Facial Reconstruction Following Skin Cancer Resection.
Lee KI., Song WS., Han SK., Moon KC., Jeong SH., Dhong ES.
Laboratory Study with a reported sample of 30 on Scar, published in Bioengineering (Basel) (2025) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Laboratory Study
- Journal
- Bioengineering (Basel) (2025)
- Country
- Switzerland
- Reported sample size
- 30
- Source database
- PubMed
- PMID
- 40001665
- PMCID
- PMC11851542
- DOI
- 10.3390/bioengineering12020145
Abstract (original English)
Our group has previously demonstrated that tissue-engineered dermis containing cultured fibroblasts or adipose-derived stromal vascular fraction cells is superior to artificial dermis in terms of scar quality for covering facial defects. However, using these cells for clinical applications requires Food and Drug Administration approval and involves complex procedures for cell culture or isolation. This retrospective study aimed to compare effects of tissue-engineered dermis containing micronized adipose tissue (MAT) and artificial dermis for facial reconstruction. Tissue-engineered dermis consisting of MAT seeded on artificial dermis was applied in 30 cases, while artificial dermis without MAT was grafted in 35 cases. Healing time and severities of scar contraction, color mismatch, and landmark distortion at one year after healing were evaluated. Wounds in the tissue-engineered dermis group re-epithelialized in 30.0 ± 4.3 days compared to 34.3 ± 5.4 days in the artificial dermis group ( p < 0.05). The average dE2000 score in color mismatch analysis was 4.9 ± 1.7 in the tissue-engineered dermis group and 5.1 ± 1.7 in the artificial dermis group ( p = 0.57). The extent of scar contraction was 16.2 ± 12.3% in the tissue-engineered dermis group and 23.2 ± 12.8% in the artificial dermis group ( p < 0.05). The average severity grade of landmark distortion was 0.20 ± 0.50 in the tissu
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.
Related research
- Level ASystematic ReviewPubMed
Clinical Applications of Autologous Fat Grafting in Pathological Hand Conditions.
Systematic Review with a reported sample of 7 on Osteoarthritis, Scar, published in J Hand Surg Asian Pac Vol (2026) — summary generated from the PubMed abstract.
- 2026
- n = 7
J Hand Surg Asian Pac Vol - Level AMeta-analysisPubMed
Stem cell therapy in thin endometrium and Asherman's syndrome: a systematic review and meta-analysis.
Meta-analysis with a reported sample of 323 on Scar, published in Eur J Obstet Gynecol Reprod Biol (2026) — summary generated from the PubMed abstract.
- 2026
- n = 323
Eur J Obstet Gynecol Reprod Biol - Level AMeta-analysisEurope PMC
Therapeutic value of mesenchymal stem cell-derived extracellular vesicles in hypertrophic and keloid scars: a systematic review and meta-analysis
Meta-analysis on Chronic Wound, Scar, published in Front Cell Dev Biol (2026) — summary generated from the PubMed abstract.
- 2026
Front Cell Dev Biol - Level AMeta-analysisPubMed
Efficacy and safety of autologous cell-based therapies for atrophic acne scar treatment: an updated systematic review and meta-analysis with in-depth methodological and clinical insights.
Meta-analysis with a reported sample of 500 on Chronic Wound, Scar, published in Front Cell Dev Biol (2026) — summary generated from the PubMed abstract.
- 2026
- n = 500
Front Cell Dev Biol - Level ASystematic ReviewEurope PMC
Comparative Efficacy and Safety of Fractional CO<sub>2</sub> Laser and Gold Microneedling Radiofrequency for Atrophic Acne Scars: A Systematic Review
Systematic Review on Chronic Wound, Scar, published in Skin Res Technol (2026) — summary generated from the PubMed abstract.
- 2026
Skin Res Technol - Level AMeta-analysisPubMed
Role of exosome therapy in reconstructive surgery: a review.
Meta-analysis on Chronic Wound, Scar, Immune Modulation, published in Front Med (Lausanne) (2026) — summary generated from the PubMed abstract.
- 2026
Front Med (Lausanne)1 citations